Hope and Hurdles for Menin Inhibitors in Leukemia

The approval of revumenib, the first menin inhibitor for KMT2A-rearranged acute leukemia, introduces a promising new targeted therapy option, though its efficacy is limited. Ongoing research into additional menin inhibitors and combination therapies aims to enhance treatment outcomes across a variety of genetically defined patient subsets.